Roivant Sciences Ltd.
—- Market cap
- —
- Debt
- +$412.94M
- Cash
- −$4.29B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ROIV stock price vs DEO: inconclusive — current versus $0.02 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DEO's multiple
Implied fair value · at ROIV's multiple
Needs ROIV P/S.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ROIV FY 2026 (ended Mar 31, 2026) · DEO FY 2025 (ended Jun 30, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 62% equity / 38% debt · EV / Revenue 3.05x · EV / EBITDA 23.14x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ROIVANT SCIENCES LTD. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
DIAGEO plc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.09x
—
Net debt / EBITDA
Leverage against operating earnings
24.52x
8.42x
Cash and equivalents
Liquid reserves on the balance sheet
$4.29B
$2.20B
Total debt
Interest-bearing obligations outstanding
$412.94M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Revolution Medicines, Inc.
ROIV vs RVMD
INCYTE CORP
ROIV vs INCY
Sarepta Therapeutics, Inc.
ROIV vs SRPT
EXELIXIS, INC.
ROIV vs EXEL
VERTEX PHARMACEUTICALS INC / MA
ROIV vs VRTX
CONSTELLATION BRANDS, INC.
ROIV vs STZ
COCA COLA CO
ROIV vs KO
PEPSICO INC
ROIV vs PEP
MOLSON COORS BEVERAGE CO
ROIV vs TAP
BOSTON BEER CO INC
ROIV vs SAM
$33.20B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.